We are live on ! Find out more
CVS icon

CVS Health

1,844 hedge funds and large institutions have $75.3B invested in CVS Health in 2019 Q4 according to their latest regulatory filings, with 255 funds opening new positions, 723 increasing their positions, 709 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

249% more first-time investments, than exits

New positions opened: 255 | Existing positions closed: 73

32% more call options, than puts

Call options by funds: $2.15B | Put options by funds: $1.63B

18% more capital invested

Capital invested by funds: $63.9B → $75.3B (+$11.5B)

15% more funds holding in top 10

Funds holding in top 10: 8497 (+13)

10% more funds holding

Funds holding: 1,6841,844 (+160)

2% more repeat investments, than reductions

Existing positions increased: 723 | Existing positions reduced: 709

0.04% more ownership

Funds ownership: 77.95%77.99% (+0.04%)

Holders
1,844
Holders Change
+160
Holders Change %
+9.5%
% of All Funds
36.33%
Holding in Top 10
97
Holding in Top 10 Change
+13
Holding in Top 10 Change %
+15.48%
% of All Funds
1.91%
New
255
Increased
723
Reduced
709
Closed
73
Calls
$2.15B
Puts
$1.63B
Net Calls
+$524M
Net Calls Change
+$375M
Name Holding Trade Value Shares
Change
Change in
Stake
WP
351
Woodline Partners
California
$11.8M +$11.1M +158,697 New
MTC
352
McDaniel Terry & Co
Texas
$11.7M +$196K +2,789 +2%
CCT
353
Country Club Trust
Missouri
$11.7M +$141K +2,013 +1%
FBP
354
Flippin Bruce & Porter
Virginia
$11.6M -$117K -1,663 -1%
OWD
355
Osborn Williams & Donohoe
Ohio
$11.6M -$815K -11,610 -7%
Brown Advisory
356
Brown Advisory
Maryland
$11.6M +$743K +10,583 +7%
MRCM
357
M&R Capital Management
New Jersey
$11.6M -$277K -3,949 -2%
MC
358
Moors & Cabot
Massachusetts
$11.5M +$370K +5,267 +4%
HCMT
359
Highland Capital Management (Tennessee)
Tennessee
$11.5M +$115K +1,641 +1%
RCYC
360
Richard C. Young & Co
Rhode Island
$11.4M +$241K +3,433 +2%
Twin Tree Management
361
Twin Tree Management
Texas
$11.3M +$7.07M +100,640 +193%
Mirae Asset Global Investments
362
Mirae Asset Global Investments
South Korea
$11.3M +$825K +11,748 +8%
MCM
363
MAI Capital Management
Ohio
$11.3M +$617K +8,793 +6%
CIC
364
Canal Insurance Company
South Carolina
$11.1M
Kovitz Investment Group Partners
365
Kovitz Investment Group Partners
Illinois
$11.1M +$9.55K +136 +0.1%
NIPH
366
NN Investment Partners Holdings
Netherlands
$11.1M +$419K +5,961 +4%
BFO
367
Boston Family Office
Massachusetts
$10.9M +$394K +5,615 +4%
RMCM
368
Reynders McVeigh Capital Management
Massachusetts
$10.8M -$43.1K -614 -0.4%
IIM
369
Intact Investment Management
Quebec, Canada
$10.8M +$358K +5,100 +4%
GH
370
GAM Holding
Switzerland
$10.6M -$2.43M -34,608 -20%
HTHT
371
Hemenway Trust Hemenway Trust
New Hampshire
$10.6M +$100K +1,426 +1%
SPIA
372
Steward Partners Investment Advisory
New York
$10.6M +$344K +4,902 +4%
WI
373
Wafra Inc
New York
$10.6M +$10M +142,428 New
PI
374
PEAK6 Investments
Illinois
$10.5M -$6.27M -89,301 -39%
MML Investors Services
375
MML Investors Services
Massachusetts
$10.4M +$973K +13,859 +11%

CVS Hedge Fund Activity: Q4 2019 in Review

1,844 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in CVS Health (CVS) for Q4 2019, worth a combined $75.3B — up 18% from $63.9B a quarter earlier.

Buyers outnumbered sellers: 255 funds opened new CVS positions and 73 closed out — a net gain of 182 holders — while 723 added to existing stakes and 709 trimmed.

The largest buyer was Capital World Investors, adding an estimated $679M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $418M.

  • 1,844 institutional investors held CVS Health (CVS) as of Q4 2019, up from 1,684 in Q3 2019.
  • Funds reported $75.3B of CVS Health stock for Q4 2019, up 18% quarter-over-quarter.
  • 255 funds opened new CVS Health positions in Q4 2019 and 73 closed out, a net change of +182 holders.
  • The largest CVS Health buyer in Q4 2019 was Capital World Investors, an estimated $679M added.
  • The largest CVS Health seller in Q4 2019 was Barrow, Hanley, Mewhinney & Strauss, an estimated $418M sold.

Based on aggregated 13F filings for Q4 2019.